ADM and Shock: A candidate drug targeting adrenomedullin, adrecizumab (a humanized, monoclonal, nonneutralizing antibody against the N terminus of ADM55), is entering phase II trials for septic shock (URL: https://www.ClinicalTrials.gov; Unique identifier: NCT03085758), cardiogenic shock (Unique identifier: NCT03989531), and acute HF (Unique identifier: NCT04252937).